METOPROLOL TARTRATE (metoroprolol tartrate) by Hikma is 1 -selective (cardioselective) adrenergic receptor blocking agent. Approved for definite, suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality, the treatment of definite. First approved in 2007.
Drug data last refreshed 19h ago
1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…
Worked on METOPROLOL TARTRATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants